The challenges faced by this sector are greater than ever in a fiercely competitive marketplace where companies need to move fast to take promising therapies from the laboratory to the market.Â Our understanding extends beyond just pure technology expertise and we understand the pressures facing the sector from loss of revenue streams and generic challenges through to pricing pressures and increased regulation.
Working with our clients, we have achieved notable success and we are often selected for high-stake cases relating to blockbuster pharmaceutical and biotechnological products and currently act for the largest players in this field.
Our extensive experience in these proceedings and our awareness of how to manage and take advantage of the procedural and substantive aspects of the law allow us to devise and present a case in the clientsâ€™ best commercial interests. For this reason, the attorneys in our group are also regularly retained by large corporations to take on difficult, commercially important opposition cases both at first instance and appeal level.
Members of our life sciences group are recognised as some of the leading UK and European practitioners within this sector
Being a part of this global community is important to us and we support a number of key events each year. We also regularly contribute to a number of industry publications.
The business of precision medicine â€“ visioning the Future
We are pleased to be Gold Sponsors of theÂ inaugural Bionow Precision Medicine Conference. Hosted in Leeds on 5th April, the conference will explore the impact that developments in this area is having on patients, particulaly in the areas of inflammatory disease, cancer, cardiovascular / metabolic, infection, health economics and clinical trials. To read more please click here.Â
Make sure to pop down to meet the team at BioTrinity at stand number 26. taking BioTrinity is one of Europe's leading industry networking and partnering conference, and is takingÂ place in London from 8th - 10th May. To read more about the conference please click here.Â
We are proud sponsors of ON Helix, a conference that aims to help delegatesÂ turn early stage inventions and ideas into innovative health treatments. Martin MacLean and Craig Titmus will be attending the conference that takes place on 13th July in Cambridge.Â
The Nagoya Protocol â€“ A Practical Overview
David Hobson has co-authored a publicationÂ The Nagoya Protocol â€“ A Practical Overview, Thomas BjÃ¸rn & David Hobson, Copenhagen Life Science (September/October 2015).Â The Nagoya Protocol aims to regulate the access to genetic resources and to ensure the fair and equitable sharing of benefits arising from their utilisation.